Agios Pharmaceuticals, Inc.

Crystal Pharmaceutical (suzhou) Co., Ltd.

Jianming Wang

Yanfeng Zhang

Chong-Hui Gu

Samuel V Agresta

David Schenkein

Hua Yang

Liting Guo

Zhen Tang

Yan Zhou

Minhua Chen

Yuan Liu

The present disclosure relates to novel crystalline forms of acalabrutinib and processes for preparation thereof. The present disclosure also relates to pharmaceutical compositions containing acalabrutinib, use of acalabrutinib for preparing Bruton's tyrosine kinase inhibitor drug, and use of acalabrutinib for preparing drugs treating mantle cell lymphoma. The crystalline forms of the present disclosure have one or more improved properties compared with prior art, and have significant value for future drug optimization and development. 

Crystal form of acalabrutinib and preparation method and use thereof

Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.

Therapeutically active compounds and their methods of use

Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.

Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes.

Growing community of inventors

Suzhou, China

Jianming Wang